TOP TEN perturbations for 38679_g_at (Homo sapiens)
Organism: Homo sapiens
Gene: 38679_g_at
Selected probe(set): 231112_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 38679_g_at (231112_at) across 6674 perturbations tested by GENEVESTIGATOR:
sangivamycin study 1 / untreated MCF-7 cell sample
Relative Expression (log2-ratio):1.8761806Number of Samples:2 / 2
| Experimental | sangivamycin study 1 |
| MCF7 cells treated with 2uM sangivamycin for 24 hours. ATC code:--- | |
| Control | untreated MCF-7 cell sample |
| MCF-7 cells untreated. |
ovarian tumor study 16 / normal ovarian surface epithelial cell sample
Relative Expression (log2-ratio):-1.8641644Number of Samples:3 / 5
| Experimental | ovarian tumor study 16 |
| Human epithelial tumor cell samples from the ovary of patients with papillary serous carcinoma. Samples were derived by laser capture microdissection (LCM). | |
| Control | normal ovarian surface epithelial cell sample |
| Human epithelial cell samples from histopathological normal and non-cancerous ovary tissue. |
dengue fever study 10 (DHF) / normal naive CD8 T cell sample
Relative Expression (log2-ratio):-1.7771311Number of Samples:2 / 5
| Experimental | dengue fever study 10 (DHF) |
| Activated CD8 T cells derived from peripheral blood mononuclear cells (PBMCs) of Thai individuals with Dengue hemorrhagic fever (DF) characterized by the WHO 1997. FACS-sorted CD3+, CD8+, HLA_DR+, and CD38+ effector CD8 T subtype cells were used for analysis. | |
| Control | normal naive CD8 T cell sample |
| Normal naive CD8 T cells derived from peripheral blood mononuclear cells (PBMCs) of healthy Thai individuals. FACS-sorted CD3+, CD8+, CD45RA+, and CCR7+ naive CD8 T subtype cells were used for analysis. |
ARC study 1 / untreated MCF-7 cell sample
Relative Expression (log2-ratio):1.764904Number of Samples:2 / 2
| Experimental | ARC study 1 |
| MCF7 cells treated with 2uM ARC (4-amino-6-hydrazino-7-beta-d-ribofuranosyl-7H-pyrrolo-(2, 3-d)-pyrimidine-5-carboxamide, NSC 188491) for 24 hours. ATC code:--- | |
| Control | untreated MCF-7 cell sample |
| MCF-7 cells untreated. |
influenza virus study 11 (A/H5N3) / influenza virus study 9 (A/H5N2)
Relative Expression (log2-ratio):-1.5989552Number of Samples:3 / 3
| Experimental | influenza virus study 11 (A/H5N3) |
| Human carcinoma cell line A549 infected with influenza A virus subtype influenza virus A/duck/Malaysia/F119/3/1997(H5N3). Samples were taken 10 hours post-infection. | |
| Control | influenza virus study 9 (A/H5N2) |
| Human carcinoma cell line A549 infected with influenza A virus subtype A/duck/Malaysia/F118/08/2004(H5N2). Samples were taken 10 hours post-infection. |
RAF1 overexpr. study 1 (retrovirus) / control virus infected MCF7 cell sample
Relative Expression (log2-ratio):1.5381804Number of Samples:2 / 2
| Experimental | RAF1 overexpr. study 1 (retrovirus) |
| MCF-7 cell line stably transfected with retrovirus containing cDNA for RAF1. The following retroviral construct was used: pLNCRaf-1 contains human Raf-1 cDNA encoding an amino terminally truncated form of Raf-1 that is constitutively active, which is inserted into retroviral vector pLNCX encoding neomycin resistance gene (NeoR). MCF7 cells were maintained in EMEM supplemented with 10% FBS and 20ug/ml insulin. | |
| Control | control virus infected MCF7 cell sample |
| MCF7 cell line transfected with pZipneo retrovirus, which is an empty retroviral vector encoding neomycine resistance gene (NeoR). MCF7 cells were maintained in EMEM supplemented with 10% FBS and 20ug/ml insulin. |
dengue fever study 10 (DF) / normal naive CD8 T cell sample
Relative Expression (log2-ratio):-1.5016403Number of Samples:3 / 5
| Experimental | dengue fever study 10 (DF) |
| Activated CD8 T cells derived from peripheral blood mononuclear cells (PBMCs) of Thai individuals with Dengue fever (DF) characterized by the WHO 1997. FACS-sorted CD3+, CD8+, CD45RA+, and CCR7+ naive CD8 T subtype cells were used for analysis. | |
| Control | normal naive CD8 T cell sample |
| Normal naive CD8 T cells derived from peripheral blood mononuclear cells (PBMCs) of healthy Thai individuals. FACS-sorted CD3+, CD8+, CD45RA+, and CCR7+ naive CD8 T subtype cells were used for analysis. |
systemic lupus erythematosus study 13 (untreated) / normal PBMC sample
Relative Expression (log2-ratio):1.4824057Number of Samples:4 / 5
| Experimental | systemic lupus erythematosus study 13 (untreated) |
| Peripheral blood mononuclear cells (PBMCs) obtained from systemic lupus erythematosus (SLE) patients. Freshly isolated PBMCs were cultured in RPMI/10% FBS for 6 hours. Lupus patients fulfilled American College of Rheumatology classification criteria for disease, and disease activity was quantified by SLEDAI. Patients were excluded if they showed symptoms of recent or active infection or were pregnant. None of the patients was taking Pioglitazone or other PPAR-γ agonists. | |
| Control | normal PBMC sample |
| Peripheral blood mononuclear cells (PBMCs) obtained from healthy subjects. Freshly isolated PBMCs were cultured in RPMI/10% FBS for 6 hours. |
esophagus cancer study 1 (PDX; squamous cell carcinoma, NOS; metastatic) / esophagus cancer study 1 (PDX; squamous cell carcinoma, NOS; primary)
Relative Expression (log2-ratio):1.4728212Number of Samples:2 / 3
| Experimental | esophagus cancer study 1 (PDX; squamous cell carcinoma, NOS; metastatic) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from a metastasis of patients with primary squamous cell carcinoma, NOS of the oesophagus (subcutaneously implanted). Metastatic site of patient tumor sample is not reported. | |
| Control | esophagus cancer study 1 (PDX; squamous cell carcinoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary squamous cell carcinoma, NOS of the oesophagus (subcutaneously implanted). |
echinomycin study 1 / deferoxamine study 5
Relative Expression (log2-ratio):1.4682198Number of Samples:3 / 3
| Experimental | echinomycin study 1 |
| Echinomycin (100nM; 2h) treated human astroglioma (U251) cells, stimulated with deferoxamine (DFO; 300mM; 16h). ATC code:--- | |
| Control | deferoxamine study 5 |
| Untreated human astroglioma (U251) cells, stimulated with deferoxamine (DFO; 300mM; 16h). ATC code: |
Organism: Homo sapiens
Gene: 38679_g_at
Selected probe(set): 203316_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 38679_g_at (203316_s_at) across 6674 perturbations tested by GENEVESTIGATOR:
glioma study 27 (glioblastoma, NOS) / glioma study 27 (pilocytic astrocytoma)
Relative Expression (log2-ratio):2.6436262Number of Samples:4 / 2
| Experimental | glioma study 27 (glioblastoma, NOS) |
| Primary tumor samples from resected brain tissues of patients with glioblastoma, NOS(WHO grade IV astrocytoma). | |
| Control | glioma study 27 (pilocytic astrocytoma) |
| Primary tumor samples from resected brain tissues of patients with pilocytic astrocytoma (WHO grade I astrocytoma). |
colorectal cancer study 4 (recurring) / adjacent colon tissue (recurring)
Relative Expression (log2-ratio):2.546628Number of Samples:24 / 3
| Experimental | colorectal cancer study 4 (recurring) |
| LCM-tumor tissue samples of patients who received resection after diagnosis of primary colorectal cancer. Patients developed metastatic recurrence during follow-up after surgery. | |
| Control | adjacent colon tissue (recurring) |
| Histologically normal colon tissue samples from patients with primary colorectal cancer collected after resection. Tissue was further extracted using laser-capture microdissection (LCM). With metastatic recurrence after resection during follow-up. |
glioma study 27 (astrocytoma, anaplastic) / glioma study 27 (pilocytic astrocytoma)
Relative Expression (log2-ratio):2.4861708Number of Samples:6 / 2
| Experimental | glioma study 27 (astrocytoma, anaplastic) |
| Primary tumor samples from resected brain tissues of patients with anaplastic astrocytoma(WHO grade III astrocytoma). | |
| Control | glioma study 27 (pilocytic astrocytoma) |
| Primary tumor samples from resected brain tissues of patients with pilocytic astrocytoma (WHO grade I astrocytoma). |
glioma study 27 (astrocytoma, NOS) / glioma study 27 (pilocytic astrocytoma)
Relative Expression (log2-ratio):2.33461Number of Samples:5 / 2
| Experimental | glioma study 27 (astrocytoma, NOS) |
| Primary tumor samples from resected brain tissues of patients with astrocytoma, NOS (WHO grade II astrocytoma). | |
| Control | glioma study 27 (pilocytic astrocytoma) |
| Primary tumor samples from resected brain tissues of patients with pilocytic astrocytoma (WHO grade I astrocytoma). |
nephroblastoma study 2 / normal kidney tissue (adult)
Relative Expression (log2-ratio):2.231804Number of Samples:4 / 3
| Experimental | nephroblastoma study 2 |
| Tumor tissue samples from the kidney of patients with Wilms' tumor. | |
| Control | normal kidney tissue (adult) |
| Normal adult kidney tissue samples. |
sirolimus study 6 (light) / sirolimus study 6 (heavy)
Relative Expression (log2-ratio):2.1358004Number of Samples:3 / 3
| Experimental | sirolimus study 6 (light) |
| Human fetal lung fibroblast cell line (MRC5) treated for 50 minutes with sirolimus (100 nM; vendor: LC laboratories / catalog name: rapamycin). Cells in the growing phase (at 60% confluency) were hypertonically shocked by changing the condition media to a 300 mM NaCl containing Medium for 30 minutes. After hypertonic shock cells were transferred back to isotonic conditions for additional 30 min. Rapamycin was added to the cells during hypertonic shock until the end of recovery (50 minutes total exposure). After treatment RNA was isolated from the light polysome fraction. ATC code:, | |
| Control | sirolimus study 6 (heavy) |
| Human fetal lung fibroblast cell line (MRC5) treated for 50 minutes with sirolimus (100 nM; vendor: LC laboratories / catalog name: rapamycin). Cells in the growing phase (at 60% confluency) were hypertonically shocked by changing the condition media to a 300 mM NaCl containing Medium for 30 minutes. After hypertonic shock cells were transferred back to isotonic conditions for additional 30 min. Rapamycin was added to the cells during hypertonic shock until the end of recovery (50 minutes total exposure). After treatment RNA was isolated from the heavy polysome fraction. ATC code:, |
T-cell activation study 4 / normal resting T-cell sample
Relative Expression (log2-ratio):2.0971422Number of Samples:2 / 2
| Experimental | T-cell activation study 4 |
| T-cell samples antiCD3 activated for 30hrs. | |
| Control | normal resting T-cell sample |
| T cells resting for 30h. |
hepatoblastoma study 1 (epithelial mixed) / normal liver tissue
Relative Expression (log2-ratio):1.961647Number of Samples:12 / 5
| Experimental | hepatoblastoma study 1 (epithelial mixed) |
| Liver tumor tissue samples from children with hepatoblastoma (epithelial type (E-HB); epithelial mixed subtype). Tumors were integrase interactor 1–negative (INI1 or SMARCB1) as recommended by the International ConsensusHBClassification group. | |
| Control | normal liver tissue |
| Normal liver tissue samples. |
glioma study 17 (glioblastoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)
Relative Expression (log2-ratio):1.9298582Number of Samples:3 / 3
| Experimental | glioma study 17 (glioblastoma; A2B5+) |
| Oligodendrocyte progenitor cells (OPC) isolated from high grade glioblastoma (grade IV). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 66 ± 5 years old males. | |
| Control | non-tumor oligodendrocyte progenitor cell sample (cortex) |
| Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. |
colorectal cancer study 4 (metastatic progression) / adjacent colon tissue (metastatic progression)
Relative Expression (log2-ratio):1.9036207Number of Samples:23 / 4
| Experimental | colorectal cancer study 4 (metastatic progression) |
| LCM-tumor tissue samples of patients who received resection after diagnosis of primary colorectal cancer with metastatic progression. | |
| Control | adjacent colon tissue (metastatic progression) |
| Histologically normal colon tissue samples from patients with primary colorectal cancer and metastatic progression collected after resection. Tissue was further extracted using laser-capture microdissection (LCM). |
Organism: Homo sapiens
Gene: 38679_g_at
Selected probe(set): 203316_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 38679_g_at (203316_s_at) across 6674 perturbations tested by GENEVESTIGATOR:
glioma study 27 (glioblastoma, NOS) / glioma study 27 (pilocytic astrocytoma)
Relative Expression (log2-ratio):2.6436262Number of Samples:4 / 2
| Experimental | glioma study 27 (glioblastoma, NOS) |
| Primary tumor samples from resected brain tissues of patients with glioblastoma, NOS(WHO grade IV astrocytoma). | |
| Control | glioma study 27 (pilocytic astrocytoma) |
| Primary tumor samples from resected brain tissues of patients with pilocytic astrocytoma (WHO grade I astrocytoma). |
colorectal cancer study 4 (recurring) / adjacent colon tissue (recurring)
Relative Expression (log2-ratio):2.546628Number of Samples:24 / 3
| Experimental | colorectal cancer study 4 (recurring) |
| LCM-tumor tissue samples of patients who received resection after diagnosis of primary colorectal cancer. Patients developed metastatic recurrence during follow-up after surgery. | |
| Control | adjacent colon tissue (recurring) |
| Histologically normal colon tissue samples from patients with primary colorectal cancer collected after resection. Tissue was further extracted using laser-capture microdissection (LCM). With metastatic recurrence after resection during follow-up. |
glioma study 27 (astrocytoma, anaplastic) / glioma study 27 (pilocytic astrocytoma)
Relative Expression (log2-ratio):2.4861708Number of Samples:6 / 2
| Experimental | glioma study 27 (astrocytoma, anaplastic) |
| Primary tumor samples from resected brain tissues of patients with anaplastic astrocytoma(WHO grade III astrocytoma). | |
| Control | glioma study 27 (pilocytic astrocytoma) |
| Primary tumor samples from resected brain tissues of patients with pilocytic astrocytoma (WHO grade I astrocytoma). |
glioma study 27 (astrocytoma, NOS) / glioma study 27 (pilocytic astrocytoma)
Relative Expression (log2-ratio):2.33461Number of Samples:5 / 2
| Experimental | glioma study 27 (astrocytoma, NOS) |
| Primary tumor samples from resected brain tissues of patients with astrocytoma, NOS (WHO grade II astrocytoma). | |
| Control | glioma study 27 (pilocytic astrocytoma) |
| Primary tumor samples from resected brain tissues of patients with pilocytic astrocytoma (WHO grade I astrocytoma). |
nephroblastoma study 2 / normal kidney tissue (adult)
Relative Expression (log2-ratio):2.231804Number of Samples:4 / 3
| Experimental | nephroblastoma study 2 |
| Tumor tissue samples from the kidney of patients with Wilms' tumor. | |
| Control | normal kidney tissue (adult) |
| Normal adult kidney tissue samples. |
sirolimus study 6 (light) / sirolimus study 6 (heavy)
Relative Expression (log2-ratio):2.1358004Number of Samples:3 / 3
| Experimental | sirolimus study 6 (light) |
| Human fetal lung fibroblast cell line (MRC5) treated for 50 minutes with sirolimus (100 nM; vendor: LC laboratories / catalog name: rapamycin). Cells in the growing phase (at 60% confluency) were hypertonically shocked by changing the condition media to a 300 mM NaCl containing Medium for 30 minutes. After hypertonic shock cells were transferred back to isotonic conditions for additional 30 min. Rapamycin was added to the cells during hypertonic shock until the end of recovery (50 minutes total exposure). After treatment RNA was isolated from the light polysome fraction. ATC code:, | |
| Control | sirolimus study 6 (heavy) |
| Human fetal lung fibroblast cell line (MRC5) treated for 50 minutes with sirolimus (100 nM; vendor: LC laboratories / catalog name: rapamycin). Cells in the growing phase (at 60% confluency) were hypertonically shocked by changing the condition media to a 300 mM NaCl containing Medium for 30 minutes. After hypertonic shock cells were transferred back to isotonic conditions for additional 30 min. Rapamycin was added to the cells during hypertonic shock until the end of recovery (50 minutes total exposure). After treatment RNA was isolated from the heavy polysome fraction. ATC code:, |
T-cell activation study 4 / normal resting T-cell sample
Relative Expression (log2-ratio):2.0971422Number of Samples:2 / 2
| Experimental | T-cell activation study 4 |
| T-cell samples antiCD3 activated for 30hrs. | |
| Control | normal resting T-cell sample |
| T cells resting for 30h. |
hepatoblastoma study 1 (epithelial mixed) / normal liver tissue
Relative Expression (log2-ratio):1.961647Number of Samples:12 / 5
| Experimental | hepatoblastoma study 1 (epithelial mixed) |
| Liver tumor tissue samples from children with hepatoblastoma (epithelial type (E-HB); epithelial mixed subtype). Tumors were integrase interactor 1–negative (INI1 or SMARCB1) as recommended by the International ConsensusHBClassification group. | |
| Control | normal liver tissue |
| Normal liver tissue samples. |
glioma study 17 (glioblastoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)
Relative Expression (log2-ratio):1.9298582Number of Samples:3 / 3
| Experimental | glioma study 17 (glioblastoma; A2B5+) |
| Oligodendrocyte progenitor cells (OPC) isolated from high grade glioblastoma (grade IV). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 66 ± 5 years old males. | |
| Control | non-tumor oligodendrocyte progenitor cell sample (cortex) |
| Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. |
colorectal cancer study 4 (metastatic progression) / adjacent colon tissue (metastatic progression)
Relative Expression (log2-ratio):1.9036207Number of Samples:23 / 4
| Experimental | colorectal cancer study 4 (metastatic progression) |
| LCM-tumor tissue samples of patients who received resection after diagnosis of primary colorectal cancer with metastatic progression. | |
| Control | adjacent colon tissue (metastatic progression) |
| Histologically normal colon tissue samples from patients with primary colorectal cancer and metastatic progression collected after resection. Tissue was further extracted using laser-capture microdissection (LCM). |